Media Coverage

A positive Lyme disease antibody result may signal a need to consider other tick-borne pathogens, according to a study of 193,260 individuals tested at Quest Diagnostics. In the U.S. Northeast, 31.1% of people positive for B. burgdorferi also tested positive for at least one of those other three pathogens, Yonghong Li, PhD, of Quest Diagnostics in San Juan Capistrano, California, and colleagues reported in a JAMA Network Open research letter.

With CMS poised to release clinical lab payment rates with statutorily mandated reductions of up to 15%, Quest Diagnostics is highlighting a survey finding that consumers across party lines view lab tests as critical to their care and is urging Congress to pass the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act before the cuts kick in on Jan. 1.

With the US Food and Drug Administration (FDA) recently clearing two blood-based Alzheimer’s tests and additional regulatory clearances expected in the near future, the market for such assays is an increasingly crowded one. he clinical laboratory firms Quest Diagnostics and Laboratory Corporation of America offer both the FDA-cleared Roche and Fujirebio tests and their own laboratory-developed Alzheimer’s blood tests. “There is a little bit of difference in the performance of the tests,” said Michael Racke, medical director for neurology at Quest. He noted, for instance, that studies have indicated mass spectrometry (used by C2N in PrecivityAD2) may offer better measurement of plasma Aβ 40/42 than immunoassays, a finding that he said influenced Quest’s decision to use mass spec for its AD-Detect Alzheimer’s LDT. Different immunoassays have also shown differences in performance, he said.

Labcorp and Quest Diagnostics see solid growth on the horizon for laboratory companies as health systems try to blunt financial headwinds and patients seek more on-demand services. After acquiring lab assets from systems such as Minneapolis-based Allina Health, Columbus, Ohio-based OhioHealth, Franklin, Tennessee-based Community Health Systems and Fort Wayne, Indiana-based Parkview Health, the two dominant national commercial laboratory companies have set their focus on broadening test menus and direct-to-patient offerings.

Quest Diagnostics announced that Apple Health app users across most of the United States will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function.

Medicare’s expansion of coverage for A1c for diabetes screening in 2024 was followed by significant increases in use of the test and detection of prediabetes, new data showed. The researchers compared laboratory data from Quest Diagnostics from January 1, 2022, to September 30, 2023, with data from the same period in 2024-2025. “This is the first study I’m aware of that specifically looks at how the testing patterns changed after Medicare adopted the rule,” said co-investigator Jason Ng, MD, clinical professor of medicine in the Division of Endocrinology and Metabolism at the University of Pittsburgh Medical Center in Pittsburgh.

Cardiologist Dr. Marc Penn joins Good Day DC. to discuss how new, advanced testing can reveal hidden cardiovascular risks that standard cholesterol panels often overlook.

Now, for the first time, you can test your biological age when you get your next round of blood work. Humanity Health Inc. and Quest Diagnostics are launching “Humanity Biological Age.” This test is available in the U.S. via questhealth.com. It’s a $29 add-on to certain existing Quest blood panels (like the Elite Health Profile or Men’s/Women’s Comprehensive Health Profiles) with no extra blood draw needed.

More than 860 North Carolinians have tested positive for Cyclospora this summer. They join thousands of Americans nationwide testing positive for the parasite at levels the country has never seen before. Two North Carolina cases have now been tied to a multistate outbreak involving shredded lettuce. A Cyclospora diagnosis requires a stool sample. In North Carolina, many of those samples during this summer’s historic rise in cases have been sent to Quest Diagnostics. “It’s been a busy summer, to say the least,” said Dr. Ann MacIntyre, senior medical director for infectious diseases at Quest Diagnostics.

Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. On a laboratory table that normally sits empty, hundreds of feces samples are arranged in stacks six vials high. They’ve traveled by ground and plane, across seven different eastern U.S. states, for one purpose: to be tested for parasites, including cyclospora. And they’re coming faster than scientists here can test them. At Quest’s Clifton lab, workers are putting in extra hours.